20 results
DEFM14A
APGN
Apexigen Inc
30 Jun 23
Proxy related to merger
4:21pm
”), elevated liver enzymes, bilirubin, fever, and colitis. Less frequent related SAEs reported in one patient each have included kidney injury, hepatic failure … demand for Apexigen’s products, injury to Apexigen’s reputation, costs to defend the related litigation, a diversion of management’s time
424B3
APGN
Apexigen Inc
10 Apr 23
Prospectus supplement
4:03pm
, CRS, elevated liver enzymes, bilirubin, fever, and colitis. Less frequent related SAEs reported in one patient each have included kidney injury … or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury
424B3
APGN
Apexigen Inc
10 Apr 23
Prospectus supplement
4:02pm
related SAEs reported in one patient each have included kidney injury, hepatic failure, bleeding, immune-mediated encephalitis, myositis, optic neuritis … , liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion
POS AM
pwtub9m6j l9y0
4 Apr 23
Prospectus update (post-effective amendment)
4:24pm
POS AM
qaieeok30aimqvjj8hv
4 Apr 23
Prospectus update (post-effective amendment)
4:23pm
424B3
ag1 13mglk6m
9 Sep 22
Prospectus supplement
4:40pm
424B3
gkaivl
9 Sep 22
Prospectus supplement
4:38pm
424B3
qngfstu kvgkgv
6 Jul 22
Prospectus supplement
4:18pm
S-4/A
bt8 4t1uyju0u0akptvi
23 May 22
Registration of securities issued in business combination transactions (amended)
8:00pm
S-4
g7rh6ozfch eutej
8 Apr 22
Registration of securities issued in business combination transactions
6:37pm
- Prev
- 1
- Next